NCT05597020: A Post Approval Study to Investigate the Efficacy of Daridorexant in Subjects With Insomnia and Comorbid Nocturia |
|
|
| Completed | 4 | 60 | Europe, US | Daridorexant, Placebo | Idorsia Pharmaceuticals Ltd. | Insomnia Disorder, Nocturia | 04/24 | 04/24 | | |
DARIDOR-ALZ, NCT05924425: Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease |
|
|
| Recruiting | 4 | 62 | Europe | Daridorexant 50 mg, Placebo, Polysomnography, Neuropsychological assessment, Questionnaires on sleep and behavioural problems, Actimetrics, 24-hour Ambulatory Blood Pressure Monitoring (ABPM, Biomarker assay | University Hospital, Montpellier, Idorsia Pharmaceuticals Ltd. | Alzheimer Disease, Insomnia Disorder, Sleep | 05/26 | 03/27 | | |
